F2 Ventures is a venture capital and private equity firm focused on investing in the biotechnology sector that was founded in 2002 and is headquartered in London, England. F2 Ventures also has an office in Geneva, Switzerland.
Notable investments made by F2 Venture partners include; AlloVir (series A and series B), TCR2 (series B), Cullinan Oncology (series A), iPrice Group (seed round), Clinical Link (venture round), Chiasma (sereis E), ProterixBio (sereis C and series D), and Chiasma (series C).
AlloVir (formerly ViraCyte) is a company that develops cell therapies for patients suffering from life-threatening virus-associated diseases.
TCR2 Therapeutics is a biotechnology company developing T cell hematologic cancer immunotherapies.
Cullinan Oncology is a Cambridge, Massachusetts-based company.